Comparison of the Efficacy of a Protocol for the Withdrawal of Neurosedation From the Usual Strategy in Cerebroses (NEUROSEV)

Centre Hospitalier Universitaire, Amiens

Status: Completed

Conditions: Withdrawal Syndrome; Cerebral Lesion

Treatments: Other: Variation of Jasinski score between H0 (stop of sedatives) and H6

Study type: Interventional

Funder types: Other

Identifiers

NCT03114904

PI2015_843_0019

Details and patient eligibility

About

The withdrawal syndrome in benzodiazepines and morphine is common in intensive care, the incidence is estimated at 32.1%.

Cerebrospatized patients are probably more prone to withdrawal because they require high doses of sedation.

Moreover, this syndrome is probably deleterious on the cerebral hemodynamics (high point of the therapeutic management).

Enrollment: 8 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Major Patient
• Admitted in Neuroreanimation
• Cerebroséé (TC-HSA-AVC)
• Mono or multi failing
• After a neurosedation ≥ 3 days by hypnotic type benzodiazepine (Midazolam®) and morphinomimetic (Sufentanyl®) in IVSE
• Affiliation to Social Security
• Agreement of the person of confidence

Exclusion criteria

• Addiction to opiates, cocaine or cannabis
• Neurological Pathology Before Hospitalization
• Patient suffering from cardiac arrest
• Pregnant woman
• Sedation window
• Patient under tutelage or curatorship or deprived of public law

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

8 participants in 2 patient groups

"Usual" weaning management

Other group

Treatment:

Other: Variation of Jasinski score between H0 (stop of sedatives) and H6

Introduction to H2 for the discontinuation of therapeutics

Other group

Treatment:

Other: Variation of Jasinski score between H0 (stop of sedatives) and H6